Trial reportBritish journal of haematology2010
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.
Trial report in British journal of haematology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Randomized, Open-label, Parallel-group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
Who cites it
32 citing papers in PubMed, 74 citations in OpenAlex.
- G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial.Blood cancer journal · 2022Trial
- Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.PloS one · 2012Trial
- Recent advances on gene-related DNA methylation in cancer diagnosis, prognosis, and treatment: a clinical perspective.Clinical epigenetics · 2025Review
- Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.Annals of hematology · 2024Article
- Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase.British journal of clinical pharmacology · 2020Article
- In MDS, is higher risk higher reward?Hematology. American Society of Hematology. Education Program · 2019Review
- Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.Medical oncology (Northwood, London, England) · 2018Review
- The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes.Medical oncology (Northwood, London, England) · 2018Article
- Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders.Oncotarget · 2017Article
- Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.Haematologica · 2016Article
- Review
- Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.International journal of molecular sciences · 2016Review
- Article
- Review
- Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process.Current treatment options in oncology · 2015Review
- DNA demethylation and invasive cancer: implications for therapeutics.British journal of pharmacology · 2015Review
- -7/7q- syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity.Oncogene · 2015Review
- Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience.American journal of hematology · 2015Article
- Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.International journal of clinical oncology · 2014Review
- Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 10 institutions in 7 countries.
Funding
Abstract
In the phase III AZA-001 trial, low-dose cytarabine (LDara-C), the most widely used low-dose chemotherapy in patients with higher-risk myelodysplastic syndrome (MDS) who are ineligible for intensive treatment, was found to be associated with poorer survival compared with azacitidine. This analysis further compared the efficacy and the toxicity of these two drug regimens. Before randomization, investigators preselected patients to receive a conventional care regimen, one of which was LDara-C. Of 94 patients preselected to LDara-C, 45 were randomized to azacitidine and 49 to LDara-C. Azacitidine patients had significantly more and longer haematological responses and increased red blood cell transfusion independence. Azacitidine prolonged overall survival versus LDara-C in patients with poor cytogenetic risk, presence of -7/del(7q), and French-American-British subtypes refractory anaemia with excess blasts (RAEB) and RAEB in transformation. When analyzed per patient year of drug exposure, azacitidine treatment was associated with fewer grade 3-4 cytopenias and shorter hospitalisation time than LDara-C in these higher-risk MDS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.